Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT1 | Q99873 | 6/20 | 0.63 |
| ▸ | NISCH | Q9Y2I1 | 7/20 | 0.57 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.51 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.51 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.51 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20198570 | 0.81 | PRMT1 (0.68) | PRMT1NISCHPRMT3EHMT2PRMT6 | |
| SCHEMBL8229714 | 0.81 | PRMT1 (0.71) | PRMT1NISCHPRMT3EHMT2PRMT6 | |
| SCHEMBL14854513 | 0.81 | PRMT1 (0.56) | PRMT1NISCHPRMT3EHMT2PRMT6 | |
| SCHEMBL8238119 | 0.80 | PRMT1 (0.69) | PRMT1NISCHPRMT3EHMT2PRMT6 | |
| SCHEMBL14854515 | 0.80 | PRMT1 (0.54) | PRMT1NISCHPRMT3EHMT2PRMT6 | |
| SCHEMBL14854514 | 0.80 | PRMT1 (0.54) | PRMT1NISCHPRMT3EHMT2PRMT6 | |
| SCHEMBL362453 | 0.78 | PRMT1 (0.68) | PRMT1NISCHPRMT3EHMT2PRMT6 | |
| SCHEMBL8235286 | 0.78 | PRMT1 (0.63) | PRMT1NISCHPRMT3EHMT2PRMT6 | |
| Hydrochloric Acid SCHEMBL3383477 | 0.77 | PRMT1 (0.66) | PRMT1NISCHPRMT3EHMT2PRMT6 | |
| SCHEMBL8235649 | 0.77 | PRMT1 (1.00) | PRMT1NISCHPRMT3EHMT2PRMT6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120035198-A1 | Antiviral Compounds and Methods of Using Thereof | AMAN MOHAMMAD JAVAD (US) | 2012-02-09 | — | — | US | disclosed |
| US-20110086877-A1 | Small Molecule Inhibitors of Botulinum Neurotoxins | BAVARI SINA | 2011-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035198-A1 | Antiviral Compounds and Methods of Using Thereof | ZC3HAV1, MAVS, ZC3HAV1L | PRMT1 1610/4885NISCH 91/4885PRMT3 675/4885 |
| US-20110086877-A1 | Small Molecule Inhibitors of Botulinum Neurotoxins | ACHE, MMP2, TIMP3 | PRMT1 2768/4885NISCH 268/4885PRMT3 2069/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.